

Status: Currently Official on 16-Feb-2025  
Official Date: Official as of 01-Nov-2017  
Document Type: USP Monographs  
DocId: GUID-16D44CC1-E147-458C-A3BE-A2EA17DA26E4\_4\_en-US  
DOI: [https://doi.org/10.31003/USPNF\\_M57440\\_04\\_01](https://doi.org/10.31003/USPNF_M57440_04_01)  
DOI Ref: au8x3

© 2025 USPC  
Do not distribute

## Norethindrone and Ethinyl Estradiol Tablets

### DEFINITION

Norethindrone and Ethinyl Estradiol Tablets contain NLT 90.0% and NMT 110.0% of the labeled amount of norethindrone ( $C_{20}H_{26}O_2$ ), and NLT 90.0% and NMT 110.0% of the labeled amount of ethinyl estradiol ( $C_{20}H_{24}O_2$ ).

### IDENTIFICATION

#### • A. THIN-LAYER CHROMATOGRAPHIC TEST

**Standard solution:** 1 mg/mL of [USP Norethindrone RS](#) and 50 µg/mL of [USP Ethinyl Estradiol RS](#) in [alcohol](#)

**Sample solution:** Crush 1 Tablet in 1 mL of [alcohol](#) in a 15-mL conical centrifuge tube, and warm to 50° for 10 min with gentle swirling. Cool, and centrifuge to obtain a clear solution.

#### Chromatographic system

(See [Chromatography \(621\)](#), [Thin-Layer Chromatography](#).)

**Mode:** TLC

**Adsorbent:** 0.25-mm layer of chromatographic silica gel and previously activated by heating at 105° for 30 min

**Application volume:** 20 µL

**Developing solvent system:** [Toluene](#) and [ethyl acetate](#) (4:1)

**Spray reagent:** [Sulfuric acid](#)–[methanol](#), prepared by cautiously adding 70 mL of [sulfuric acid](#) in small increments to 30 mL of [methanol](#) chilled in an ice-bath, and mixing

#### Analysis

**Samples:** *Standard solution* and *Sample solution*

Apply both *Standard solution* and *Sample solution* at a line 2.5 cm from the bottom of a thin-layer chromatographic plate. Develop the chromatogram in *Developing solvent system* until the solvent front has moved 10 cm. Remove the plate, and air-dry. Spray the plate with *Spray reagent*.

**Acceptance criteria:** The spots from the *Sample solution* have the same  $R_f$  values as the spots from [USP Ethinyl Estradiol RS](#) and from [USP Norethindrone RS](#).

### ASSAY

#### • PROCEDURE

**Mobile phase:** [Acetonitrile](#) and [water](#) (60:40)

**Diluent:** [Acetonitrile](#) and [water](#) (45:55)

**Internal standard solution:** Transfer 15 mg of valerophenone into a 250-mL volumetric flask, add 125 mL of [acetonitrile](#), and dilute with [water](#) to volume.

**Ethinyl estradiol standard stock solution:** 0.09 mg/mL of [USP Ethinyl Estradiol RS](#) in [acetonitrile](#)

**Norethindrone standard stock solution:** 1.25 mg/mL of [USP Norethindrone RS](#) in [acetonitrile](#)

**Standard solution:** Transfer 5.0 mL of *Internal standard solution* into a 100-mL volumetric flask. Add volumes of *Ethinyl estradiol standard stock solution* and *Norethindrone standard stock solution* so that the final known concentrations, in mg/mL, of the Reference Standards correspond numerically to one-twentieth of the labeled amounts of the corresponding ingredients in the Tablets. Add  $(26 - X)$  mL of [acetonitrile](#),  $X$  being the total volume of the standard stock solution taken. Dilute with *Diluent* to volume.

**Sample stock solution:** Transfer 10 Tablets to a 100-mL volumetric flask, add 20 mL of [water](#), and shake by mechanical means until the Tablets are completely disintegrated. Add 10.0 mL of *Internal standard solution* and 60 mL of [acetonitrile](#), and mix. Sonicate for 2 min. Dilute with [acetonitrile](#) to volume, and mix. Allow solid particles to settle, or centrifuge if necessary to obtain a slightly turbid solution.

**Sample solution:** Dilute 5.0 mL of the *Sample stock solution* with *Diluent* to 10.0 mL.

#### Chromatographic system

(See [Chromatography \(621\)](#), [System Suitability](#).)

**Mode:** LC

**Detector:** UV 200 nm**Column:** 4.6-mm × 25-cm; packing [L1](#)**Flow rate:** 1 mL/min**Injection volume:** 25 µL**System suitability****Sample:** *Standard solution*

[NOTE—The relative retention times for ethinyl estradiol and norethindrone are 0.9 and 1.0, respectively.]

**Suitability requirements****Resolution:** NLT 2.0 between norethindrone and ethinyl estradiol**Column efficiency:** NLT 8000 theoretical plates from the internal standard peak**Relative standard deviation:** NMT 2.0% for six replicate injections for norethindrone and ethinyl estradiol**Analysis****Samples:** *Standard solution* and *Sample solution*Calculate the percentage of norethindrone ( $C_{20}H_{26}O_2$ ) and ethinyl estradiol ( $C_{20}H_{24}O_2$ ) in each Tablet:

$$\text{Result} = (R_U/R_S) \times (C_S/C_U) \times 100$$

 $R_U$  = peak response ratio, at corresponding retention times, of the *Sample solution* $R_S$  = peak response ratio, at corresponding retention times, of the *Standard solution* $C_S$  = concentration of the corresponding USP Reference Standard in the *Standard solution* (mg/mL) $C_U$  = nominal concentration of the corresponding sample in the *Sample solution* (mg/mL)**Acceptance criteria:** 90.0%–110.0% of the labeled amount of norethindrone ( $C_{20}H_{26}O_2$ ), and 90.0%–110.0% of the labeled amount of ethinyl estradiol ( $C_{20}H_{24}O_2$ )**PERFORMANCE TESTS**• **[DISSOLUTION \(711\)](#)**

[NOTE—Exercise care in filtering and handling solutions containing ethinyl estradiol to prevent adsorptive loss of the drug. Centrifugation may be used instead of filtration with nonadsorptive membrane filters. Withdraw dissolution aliquots with glass or polytetrafluoroethylene pipets or syringes that have been checked for adsorptive loss. Use glass dissolution vessels and polytetrafluoroethylene-coated or solid polytetrafluoroethylene paddles.]

**Test 1****Medium:** 0.09% sodium dodecyl sulfate in [0.1 N hydrochloric acid](#); 500 mL**Apparatus 2:** 75 rpm**Time:** 60 min**Buffer:** 0.02 M pH 6.0 phosphate buffer**Mobile phase:** [Acetonitrile](#) and *Buffer* (35:65)**Standard solution:** [USP Norethindrone RS](#) and [USP Ethinyl Estradiol RS](#) in *Medium* with concentrations similar to those expected in the solution under test. [NOTE—A volume of [methanol](#) not exceeding 4% of the total final volume of the *Standard solution* may be used in preparing the *Standard solution*.]**Sample solution:** A filtered portion of the solution under test.**Chromatographic system**(See [Chromatography \(621\)](#), *System Suitability*.)**Mode:** LC**Detector:** UV 200 nm**Column:** 5-mm × 8.3-cm; 3-µm packing [L1](#)**Flow rate:** 1 mL/min**Injection volume:** 100 µL**System suitability****Sample:** *Standard solution*

[NOTE—The relative retention times for norethindrone and ethinyl estradiol are 0.9 and 1.0, respectively.]

**Suitability requirements****Resolution:** NLT 1.5 between norethindrone and ethinyl estradiol**Column efficiency:** NLT 7000 theoretical plates for the ethinyl estradiol peak**Tailing factor:** NMT 2.0 for either peak

**Relative standard deviation:** NMT 3.0%

#### Analysis

**Samples:** *Standard solution* and *Sample solution*

Calculate the percentage of the labeled amount of norethindrone ( $C_{20}H_{26}O_2$ ) and ethinyl estradiol ( $C_{20}H_{24}O_2$ ) dissolved by comparison of the corresponding peak responses of the *Standard solution* and the solution under test.

**Tolerances:** NLT 75% (Q) of each of the labeled amounts of norethindrone ( $C_{20}H_{26}O_2$ ) and ethinyl estradiol ( $C_{20}H_{24}O_2$ ), respectively, are dissolved in 60 min.

**Test 2:** If the product complies with this test, the labeling indicates that it meets USP *Dissolution Test 2*.

**Medium:** 0.09% (w/v) [sodium dodecyl sulfate](#) in [0.1 N hydrochloric acid](#); 500 mL

**Apparatus 2:** 75 rpm

**Time:** 30 min

**Buffer:** 0.02 M pH 6.0 phosphate buffer prepared as follows. Dissolve 2.72 g of [potassium phosphate, monobasic](#) in 1 L of [water](#). Adjust with 10% [potassium hydroxide](#) solution in [water](#) to a pH of 6.0.

**Mobile phase:** [Acetonitrile](#) and *Buffer* (42:58)

**Standard stock solution 1:** 100 µg/mL of [USP Norethindrone RS](#) in [acetonitrile](#). Sonicate to dissolve as needed.

**Standard stock solution 2:** 3.5 µg/mL of [USP Ethinyl Estradiol RS](#) in [acetonitrile](#). Sonicate to dissolve as needed.

**Standard solution:** 0.8 µg/mL of [USP Norethindrone RS](#) and 0.07 µg/mL of [USP Ethinyl Estradiol RS](#) in *Medium*, from *Standard stock solution 1* and *Standard stock solution 2*.

**Sample solutions:** Centrifuge a portion of the solution under test at about 3000 rpm for 3 min, and use the clear supernatant.

#### Chromatographic system

(See [Chromatography \(621\), System Suitability](#).)

**Mode:** LC

**Detector:** UV 200 nm

**Column:** 4.6-mm × 10-cm; 3-µm packing [L1](#)

**Flow rate:** 0.8 mL/min

**Injection volume:** 100 µL

**Run time:** NLT 2 times the retention time of ethinyl estradiol

#### System suitability

**Sample:** *Standard solution*

[NOTE—The relative retention times for norethindrone and ethinyl estradiol are 0.9 and 1.0, respectively.]

#### Suitability requirements

**Resolution:** NLT 1.5 between norethindrone and ethinyl estradiol

**Tailing factor:** NMT 2.0 for norethindrone and ethinyl estradiol

**Relative standard deviation:** NMT 3.0% for norethindrone and ethinyl estradiol

#### Analysis

**Samples:** *Standard solution* and *Sample solution*

Calculate the percentage of the labeled amount of norethindrone ( $C_{20}H_{26}O_2$ ) and ethinyl estradiol ( $C_{20}H_{24}O_2$ ) dissolved:

$$\text{Result} = (r_U/r_S) \times C_S \times V \times (1/L) \times 100$$

$r_U$  = peak response of norethindrone or ethinyl estradiol from the *Sample solution*

$r_S$  = peak response of corresponding USP Reference Standard from the *Standard solution*

$C_S$  = concentration of the corresponding USP Reference Standard in the *Standard solution* (µg/mL)

$V$  = volume of *Medium*, 500 mL

$L$  = label claim of norethindrone or ethinyl estradiol (µg/Tablet)

**Tolerances:** NLT 80% (Q) of each of the labeled amounts of norethindrone ( $C_{20}H_{26}O_2$ ) and ethinyl estradiol ( $C_{20}H_{24}O_2$ ), respectively, are dissolved in 30 min.

**Test 3:** If the product complies with this test, the labeling indicates that it meets USP *Dissolution Test 3*.

**Medium:** 0.09% (w/v) [sodium dodecyl sulfate](#) in [0.1 N hydrochloric acid](#); 500 mL

**Apparatus 2:** 75 rpm

**Time:** 30 min

**Buffer:** 0.02 M pH 6.0 phosphate buffer prepared as follows. Dissolve 2.72 g of [potassium phosphate, monobasic](#) in 1 L of [water](#). Adjust with 0.1 N [sodium hydroxide](#) solution in [water](#) to a pH of 6.0.

**Mobile phase:** [Acetonitrile](#) and *Buffer* (38:62)

**Norethindrone standard stock solution:** 0.8 mg/mL of [USP Norethindrone RS](#) in [methanol](#). Sonicate to dissolve as needed.

**Ethinyl estradiol standard stock solution:** 0.135 mg/mL of [USP Ethinyl Estradiol RS](#) in [methanol](#). Sonicate to dissolve as needed.

**Standard solution:** [USP Norethindrone RS](#) and [USP Ethinyl Estradiol RS](#) in *Medium* with concentrations similar to those expected in the solution under test, from *Norethindrone standard stock solution* and *Ethinyl estradiol standard stock solution*. Add intermediate diluting steps as needed.

**Sample solution:** Pass a portion of the solution under test through a filter of 0.45-µm pore size and use the clear filtrate.

#### Chromatographic system

(See [Chromatography \(621\)](#), [System Suitability](#).)

**Mode:** LC

**Detector:** UV 200 nm

**Column:** 4.6-mm × 10-cm; 3-µm packing [L1](#)

**Column temperature:** 30°

**Flow rate:** 1 mL/min

**Injection volume:** 100 µL

**Run time:** NLT 1.4 times the retention time of ethinyl estradiol

#### System suitability

**Sample:** *Standard solution*

[NOTE—The relative retention times for norethindrone and ethinyl estradiol are 0.9 and 1.0, respectively.]

#### Suitability requirements

**Resolution:** NLT 1.5 between norethindrone and ethinyl estradiol

**Tailing factor:** NMT 2.0 for norethindrone and ethinyl estradiol

**Relative standard deviation:** NMT 3.0% for norethindrone and ethinyl estradiol

#### Analysis

**Samples:** *Standard solution* and *Sample solution*

Calculate the percentage of the labeled amount of norethindrone ( $C_{20}H_{26}O_2$ ) and ethinyl estradiol ( $C_{20}H_{24}O_2$ ) dissolved:

$$\text{Result} = (r_U/r_S) \times C_S \times V \times (1/L) \times 100$$

$r_U$  = peak response of norethindrone or ethinyl estradiol from the *Sample solution*

$r_S$  = peak response of corresponding USP Reference Standard from the *Standard solution*

$C_S$  = concentration of the corresponding USP Reference Standard in the *Standard solution* (µg/mL)

$V$  = volume of *Medium*, 500 mL

$L$  = label claim of norethindrone or ethinyl estradiol (µg/Tablet)

**Tolerances:** NLT 80% (Q) of each of the labeled amounts of norethindrone ( $C_{20}H_{26}O_2$ ) and ethinyl estradiol ( $C_{20}H_{24}O_2$ ), respectively, are dissolved in 30 min.

- **UNIFORMITY OF DOSAGE UNITS (905), [Content Uniformity](#):** Meet the requirements with respect to norethindrone and to ethinyl estradiol

#### ADDITIONAL REQUIREMENTS

- **PACKAGING AND STORAGE:** Preserve in well-closed containers.
- **LABELING:** When more than one *Dissolution* test is given, the labeling states the *Dissolution* test used only if *Test 1* is not used.
- **USP REFERENCE STANDARDS (11).**  
[USP Ethinyl Estradiol RS](#)  
[USP Norethindrone RS](#)

**Auxiliary Information** - Please [check for your question in the FAQs](#) before contacting USP.

Topic/Question	Contact	Expert Committee
NORETHINDRONE AND ETHINYL ESTRADIOL TABLETS	<a href="#">Documentary Standards Support</a>	SM52020 Small Molecules 5

Topic/Question	Contact	Expert Committee
REFERENCE STANDARD SUPPORT	RS Technical Services <a href="mailto:RSTECH@usp.org">RSTECH@usp.org</a>	SM52020 Small Molecules 5

Chromatographic Database Information: [Chromatographic Database](#)

Most Recently Appeared In:

Pharmacopeial Forum: Volume No. PF 43(6)

Current DocID: GUID-16D44CC1-E147-458C-A3BE-A2EA17DA26E4\_4\_en-US  
Previous DocID: GUID-16D44CC1-E147-458C-A3BE-A2EA17DA26E4\_2\_en-US  
DOI: [https://doi.org/10.31003/USPNF\\_M57440\\_04\\_01](https://doi.org/10.31003/USPNF_M57440_04_01)  
DOI ref: [au8x3](#)

OFFICIAL